Evidence map›Paper›PMID 32884453›Full record

ReviewReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology

Good or not good: Role of miR-18a in cancer biology.

Tomasz Kolenda, Kacper Guglas, Magda Kopczyńska, Joanna Sobocińska, Anna Teresiak, Renata Bliźniak, Katarzyna Lamperska

Open access · diamondAbstract readReview
In one paragraph

Review in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
4.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 89 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Biomedicines · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Association of miRNA-17-92 Cluster with Muscle Invasion in Bladder Cancer.International journal of molecular sciences · 2025
    Article
  10. Review
  11. Article
  12. miRNA-503 inhibition exerts anticancer effects and reduces tumor growth in mesothelioma.Journal of experimental & clinical cancer research : CR · 2025
    Article
  13. Characterizing the pan-cancer role of exosomal miRNAs in metastasis across cancers.Computational and structural biotechnology journal · 2025
    Article
  14. Pseudogenes in the carcinogenesis: epithelial-to-mesenchymal transition process and cancer initiating cells.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025
    Review
  15. Chemopreventive and therapeutic effects ofFrontiers in pharmacology · 2025
    Article
  16. Observational
  17. Characterizing the role of exosomal miRNAs in metastasis.bioRxiv : the preprint server for biology · 2024
    Article
  18. Non-Coding RNAs Extended Omnigenic Module of Cancers.Entropy (Basel, Switzerland) · 2024
    Article
  19. Diagnostic Potential ofInternational journal of molecular sciences · 2024
    Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Tomasz KolendaLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Kacper GuglasLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Magda KopczyńskaLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Joanna SobocińskaDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Anna TeresiakLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Renata BliźniakLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Katarzyna LamperskaLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Greater Poland Cancer Center · PLPoznan University of Medical Sciences · PLMedical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

miR-18a is a member of primary transcript called miR-17-92a (C13orf25 or MIR17HG) which also contains five other miRNAs: miR-17, miR-19a, miR-20a, miR-19b and miR-92a. This cluster as a whole shows specific characteristics, where miR-18a seems to be unique. In contrast to the other members, the expression of miR-18a is additionally controlled and probably functions as its own internal controller of the cluster. miR-18a regulates many genes involved in proliferation, cell cycle, apoptosis, response to different kinds of stress, autophagy and differentiation. The disturbances of miR-18a expression are observed in cancer as well as in different diseases or pathological states. The miR-17-92a cluster is commonly described as oncogenic and it is known as 'oncomiR-1', but this statement is a simplification because miR-18a can act both as an oncogene and a suppressor. In this review we summarize the current knowledge about miR-18a focusing on its regulation, role in cancer biology and utility as a potential biomarker.

Indexed as

5-FU, 5-fluorouracylACVR2A, activin A receptor type 2AAKT, AKT serine/threonine kinaseAR, androgen receptorATG7, autophagy related 7ATM, ATM serine/threonine kinaseBAX, BCL2 associated Xapoptosis regulatorBCL2, BCL2 apoptosis regulatorBCL2L10, BCL2 like 10BDNF, brain derived neurotrophic factorBiomarkerBLCA, bladder urothelial carcinomaBp, base pairBRCA, breast cancerCancerCASC2, cancer susceptibility 2CD133 (PROM1), prominin 1CDC42, cell division cycle 42CDKN1, Bcyclin dependent kinase inhibitor 1BceRNA, competitive endogenous RNACirculating miRNAC-myc (MYCBP), MYC binding proteincncRNA, protein coding and non-coding RNACOAD, colon adenocarcinomaDDR, DNA damage repairE2F family (E2F1, E2F2, E2F3), E2F transcription factorsEBV, Epstein-Barr virusEMT, epithelial-to-mesenchymal transitionERBB (EGFR), epidermal growth factor receptorER, estrogen receptorESCA, esophageal carcinomaFENDRR, FOXF1 adjacent non-coding developmental regulatory RNAFER1L4, fer-1 like family member 4 (pseudogene)GAS5, growth arrest–specific 5HIF-1α (HIF1A), hypoxia inducible factor 1 subunit alphaHNRNPA1, heterogeneous nuclear ribonucleoprotein A1HNSC, head and neck squamous cell carcinomaHRR, homologous recombination-based DNA repairIFN-γ (IFNG), interferon gammaIGF1, insulin like growth factor 1IL6, interleukin 6IPMK, inositol phosphate multikinaseKIRC, clear cell kidney carcinomaKIRP, kidney renal papillary cell carcinomaKRAS, KRAS proto-oncogene, GTPaseLIHC, liver hepatocellular carcinomaLiquid biopsyLMP1, latent membrane protein 1lncRNA, long-non coding RNALUAD, lung adenocarcinomaLUSC, lung squamous cell carcinomaMAPK, mitogen-activated protein kinaseMCM7, minichromosome maintenance complex component 7MET, mesenchymal-to-epithelial transitionmiR-17-92amiR-18amiRNAMTOR, mechanistic target of rapamycin kinaseNF-κB, nuclear factor kappa-light-chain-enhancer of activated B cellsN-myc (MYCN), MYCN proto-oncogene, bHLH transcription factorNOTCH2, notch receptor 2OncogenePAAD, pancreatic adenocarcinomaPERK (EIF2AK3), eukaryotic translation initiation factor 2 alpha kinase 3PI3K (PIK3CA), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaPIAS3, protein inhibitor of activated STAT 3PRAD, prostate adenocarcinomaRISC, RNA-induced silencing complexSMAD2, SMAD family member 2SMG1, SMG1 nonsense mediated mRNA decay associated PI3K related kinaseSNHG1, small nucleolar RNA host gene 1SOCS5, suppressor of cytokine signaling 5STAD, stomach adenocarcinomaSTAT3, signal transducer and activator of transcription 3STK4, serine/threonine kinase 4SuppressorTCGATCGA, The Cancer Genome AtlasTGFBR2, transforming growth factor beta receptor 2TGF-β (TGFB1), transforming growth factor beta 1THCA, papillary thyroid carcinomaTNM, Classification of Malignant Tumors: T - tumor / N - lymph nodes / M – metastasisTP53TG1, TP53 target 1TP53, tumor protein p53TRIAP1, p53-regulating inhibitor of apoptosis geneTSC1, TSC complex subunit 1UCA1, urothelial cancer associated 1UCEC, uterine corpus endometrial carcinomaUTR, untranslated regionWDFY3-AS2, WDFY3 antisense RNA 2WEE1, WEE1 G2 checkpoint kinaseWNT family, Wingless-type MMTV integration site family/Wnt family ligandsZEB1/ZEB2, zinc finger E-box binding homeobox 1 and 2

Identifiers

PMID32884453
PMCPMC7451592
OpenAlexW3048741563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.